Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS).
Guillain-Barre Syndrome
Hypoalbuminemia
Intravenous Immunoglobulin
Serum albumin
Journal
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
ISSN: 1532-2653
Titre abrégé: J Clin Neurosci
Pays: Scotland
ID NLM: 9433352
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
02
11
2019
accepted:
12
01
2020
pubmed:
24
2
2020
medline:
18
8
2020
entrez:
24
2
2020
Statut:
ppublish
Résumé
Patients with GBS may develop hypoalbuminemia following treatment with Intravenous Immunoglobulin (IVIG), which is related to a poorer outcome. This report presents a patient with GBS and his clinical response to two courses of IVIG treatments in association with his albumin level. A previously healthy 21-year-old male was admitted to the GICU due to GBS with severity grade 5 (required assisted ventilation). IVIG treatment was initiated. Over the next two weeks there was no clinical improvement and Albumin level dropped from 4.5 gr/dL to a nadir of 2.3 gr/dL. A second course of IVIG was initiated. After initiation of the second course the patient's albumin began rising to 3.0 gr/dL and a clinical improvement followed this rise. Subsequently, he was weaned from mechanical ventilation within a few days. When considering a second course of IVIG treatment, serum albumin levels may be considered a biomarker as part of the decision algorithm.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with GBS may develop hypoalbuminemia following treatment with Intravenous Immunoglobulin (IVIG), which is related to a poorer outcome. This report presents a patient with GBS and his clinical response to two courses of IVIG treatments in association with his albumin level.
CASE REPORT
METHODS
A previously healthy 21-year-old male was admitted to the GICU due to GBS with severity grade 5 (required assisted ventilation). IVIG treatment was initiated. Over the next two weeks there was no clinical improvement and Albumin level dropped from 4.5 gr/dL to a nadir of 2.3 gr/dL. A second course of IVIG was initiated. After initiation of the second course the patient's albumin began rising to 3.0 gr/dL and a clinical improvement followed this rise. Subsequently, he was weaned from mechanical ventilation within a few days.
CONCLUSIONS
CONCLUSIONS
When considering a second course of IVIG treatment, serum albumin levels may be considered a biomarker as part of the decision algorithm.
Identifiants
pubmed: 32088107
pii: S0967-5868(19)32165-4
doi: 10.1016/j.jocn.2020.01.067
pii:
doi:
Substances chimiques
Albumins
0
Biomarkers
0
Immunoglobulins, Intravenous
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-249Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.